# Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

> **NCT00815594** · PHASE4 · UNKNOWN · sponsor: **Capital Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Bleb Vascularity
- Conjunctival Scarring

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00815594
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-05
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00815594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00815594, "Bleb Vascularity Change After Subconjunctival Injection Bevacizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00815594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*